IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | $85.00 | Equal-Weight → Overweight | Morgan Stanley |
| 11/4/2024 | $66.00 → $110.00 | Outperform → Strong Buy | Raymond James |
| 10/23/2024 | $89.00 | Buy | Jefferies |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 8/22/2024 | $75.00 | Overweight | Wells Fargo |
| 4/1/2024 | $40.00 | Strong Buy → Outperform | Raymond James |
| 12/19/2023 | $56.00 → $65.00 | Overweight → Equal-Weight | Morgan Stanley |
| 6/9/2023 | $50.00 → $75.00 | Outperform → Strong Buy | Raymond James |
| 6/7/2023 | $55.00 | Buy | H.C. Wainwright |
| 5/17/2023 | $50.00 | Outperform | Raymond James |
Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for accelerated approval based on existing dataPresented proof-of-mechanism data for Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia at the American Society of Nephrology (ASN) Kidney Week 2024Eight posters and an oral presentation across all three clinical-stage assets to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionStrong financial position ending Q3 with $487 million in cash, cash equivalents, and m
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Rahul Rajan Kaushik, Ph.D. as the company's Chief Technical Officer. Dr. Kaushik is an experienced biotech executive with significant expertise in chemistry, manufacturing, and controls (CMC) leadership across technical development, manufacturing and supply chain oversight for products in multiple modalities and therapeutic areas. "Rahul's experience is an ideal fit for Disc as we evolve in
WATERTOWN, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Steve Caffé, MD as the company's Chief Regulatory Officer. Dr. Caffé is an experienced biotech executive with significant expertise in global regulatory leadership across a wide range of therapeutic areas, including hematology, oncology, and rare diseases. "We are excited to welcome an executive as accomplished as Steve to Disc, where his depth of regulatory expertise and experience in glo
WATERTOWN, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Pamela Stephenson, MPH as the company's Chief Commercial Officer. Ms. Stephenson is an experienced biotech executive with significant expertise in commercial and strategic leadership, particularly in therapies for rare diseases, and will be responsible for all aspects of Disc's global commercialization strategy and execution. "We are delighted to welcome an accomplished leader such as Pam
Jean Franchi is an industry veteran and brings over 30 years of leadership experience in finance, investor relations, capital formation, and operations at both development and commercial-stage companiesJonathan Yu, previously Chief Business Officer at Disc, has been promoted to Chief Operating Officer WATERTOWN, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Jean Franchi as the company's Chief Financial Officer. Ms. Franchi will be responsible
WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON) ("Disc"), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that, after a distinguished 28-year career, including over 6 years at Disc, Brian MacDonald, MB, ChB, PhD, will be retiring from his role as Chief Innovation Officer. Dr. MacDonald plans to stay involved with Disc, transitioning from his current role to become Chair of Disc's Scientific Advisory Board. "We are incredibly grateful for all of Brian's exceptional contributions and leadership over the pa
WATERTOWN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at two upcoming investor conferences: Stifel 2024 Healthcare Conference on Tuesday, November 19th at 8:35 a.m. ET. Jefferies London Healthcare Conference on Thursday, November 21st at 9:30 a.m. GMT. A live webcast of the presentations will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be av
Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for accelerated approval based on existing dataPresented proof-of-mechanism data for Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia at the American Society of Nephrology (ASN) Kidney Week 2024Eight posters and an oral presentation across all three clinical-stage assets to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionStrong financial position ending Q3 with $487 million in cash, cash equivalents, and m
Facility significantly increases future financial and operational flexibilityUp to $200M available, with $30 million drawn at close and additional $80 million available at Disc's sole discretion through second-half 2026Funding can support development across the portfolio, including the recently announced potential accelerated approval pathway for bitopertin in EPP WATERTOWN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it has obtained a $200 million non-dilut
Oral presentation of complete data from Phase 1b trial of DISC-0974 in anemia of myelofibrosis (MF) Poster presentations across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indicationsManagement will host a conference call during the ASH meeting on Sunday, December 8 at 9:00pm EST / 6:00pm PST WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announ
Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of average monthly time in sunlight during the last month following a 6-month treatment periodPotential for accelerated approval based on existing data and utilizing reduction of PPIX as a surrogate endpointPlan to initiate APOLLO trial, a 6-month study of a 60 mg dose of bitopertin in EPP and XLP patients ages 12+ by mid-2025Management will host a conference call on Monday, November 4 at 8:00 am EST WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on th
WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). The conference call will be held on Monday, November 4, at 8:00 am EST. Conference Call Information Please register for the event on the Events and Presentations page of Disc's website at https://ir.discmedicine.com/. About Bitopertin Bitopertin is an investigational, clinical-s
WATERTOWN, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive additional data from an ongoing Phase 1b study of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia, including results from the 40 mg and 60 mg single ascending dose (SAD) cohorts. The data presented at the 2024 American Society of Nephrology (ASN) Kidney Week in San Diego, CA demonstrated that a single dose of DISC-0974 results in sustained suppression of h
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Rahul Rajan Kaushik, Ph.D. as the company's Chief Technical Officer. Dr. Kaushik is an experienced biotech executive with significant expertise in chemistry, manufacturing, and controls (CMC) leadership across technical development, manufacturing and supply chain oversight for products in multiple modalities and therapeutic areas. "Rahul's experience is an ideal fit for Disc as we evolve in
WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced upcoming clinical data to be presented at the 2024 American Society of Nephrology (ASN) Kidney Week, which will be held in San Diego, CA on October 24-27, 2024. The poster will report on additional SAD cohorts from the Phase 1b, randomized, placebo-controlled study of DISC-0974 in patients with non-dialysis dependent chronic kidney disease (NDD CKD) and anemia. This study was designed to assess safety as well
WATERTOWN, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Steve Caffé, MD as the company's Chief Regulatory Officer. Dr. Caffé is an experienced biotech executive with significant expertise in global regulatory leadership across a wide range of therapeutic areas, including hematology, oncology, and rare diseases. "We are excited to welcome an executive as accomplished as Steve to Disc, where his depth of regulatory expertise and experience in glo
SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13G - Disc Medicine, Inc. (0001816736) (Subject)
SC 13G - Disc Medicine, Inc. (0001816736) (Subject)
SC 13D/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13D/A - Disc Medicine, Inc. (0001816736) (Subject)
Oral presentation of complete data from Phase 1b trial of DISC-0974 in anemia of myelofibrosis (MF) Poster presentations across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indicationsManagement will host a conference call during the ASH meeting on Sunday, December 8 at 9:00pm EST / 6:00pm PST WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announ
Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of average monthly time in sunlight during the last month following a 6-month treatment periodPotential for accelerated approval based on existing data and utilizing reduction of PPIX as a surrogate endpointPlan to initiate APOLLO trial, a 6-month study of a 60 mg dose of bitopertin in EPP and XLP patients ages 12+ by mid-2025Management will host a conference call on Monday, November 4 at 8:00 am EST WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on th
WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). The conference call will be held on Monday, November 4, at 8:00 am EST. Conference Call Information Please register for the event on the Events and Presentations page of Disc's website at https://ir.discmedicine.com/. About Bitopertin Bitopertin is an investigational, clinical-s
Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX (PPIX) compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light tolerance, including the key secondary endpoint, in both 20 mg and 60 mg dose groups, but did not meet statistical significance compared to placeboDose-dependent reductions in the rate of phototoxic reactions with pain, with statistical significance at the 60 mg dose group compared to placeboDose-dependent improvements in the Patient Global Impression of Change (PGIC), with statistical significance at the 60 mg dose group compared to placeboInvestor webcast at 8:30 am ET to discuss top-line data
Updated data from BEACON continued to demonstrate significant, consistent reductions in protoporphyrin IX (PPIX) > 40% and improvements in sunlight toleranceRobust and consistent improvements across all measures of sunlight tolerance, including >3x improvement over historical control of precedented pivotal endpointBitopertin was generally well-tolerated with stable hemoglobin at both dose levelsEarlier today, Disc also announced initial positive data from the phase 1b study of DISC-0974 in myelofibrosis patients with anemia, demonstrating improvements in hemoglobin and reductions in transfusion burden WATERTOWN, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a
Completion of enrollment for phase 2 BEACON and AURORA studies of bitopertin in erythropoietic protoporphyria (EPP)Oral presentation at ASH meeting of updated interim data from BEACON, including a preliminary analysis of the precedented pivotal endpoint, cumulative time in sunlight over 6 months on days without painCompany will present preliminary data on pharmacodynamic activity from initial cohorts of phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia, including changes in hemoglobinManagement will host a conference call on December 11th at 9:30 pm ET / 6:30 pm PT WATERTOWN, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage
Consistent and dose-dependent reductions of protoporphyrin IX (PPIX), the disease-causing metabolite in EPP, were observed in patients treated with bitopertin Patients reported significant improvements in sunlight tolerance and measures of quality-of-lifeBitopertin was well-tolerated, with no meaningful changes in hemoglobin observedDisc Medicine to host an investor conference call today at 7:30 AM ET WATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presente
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
Morgan Stanley upgraded Disc Medicine from Equal-Weight to Overweight and set a new price target of $85.00
Raymond James upgraded Disc Medicine from Outperform to Strong Buy and set a new price target of $110.00 from $66.00 previously
Jefferies initiated coverage of Disc Medicine with a rating of Buy and set a new price target of $89.00
Scotiabank initiated coverage of Disc Medicine with a rating of Sector Outperform
Wells Fargo initiated coverage of Disc Medicine with a rating of Overweight and set a new price target of $75.00
Raymond James downgraded Disc Medicine from Strong Buy to Outperform and set a new price target of $40.00
Morgan Stanley downgraded Disc Medicine from Overweight to Equal-Weight and set a new price target of $65.00 from $56.00 previously
Raymond James upgraded Disc Medicine from Outperform to Strong Buy and set a new price target of $75.00 from $50.00 previously
H.C. Wainwright initiated coverage of Disc Medicine with a rating of Buy and set a new price target of $55.00
Raymond James initiated coverage of Disc Medicine with a rating of Outperform and set a new price target of $50.00
EFFECT - Disc Medicine, Inc. (0001816736) (Filer)
424B5 - Disc Medicine, Inc. (0001816736) (Filer)
POS AM - Disc Medicine, Inc. (0001816736) (Filer)
8-K - Disc Medicine, Inc. (0001816736) (Filer)
8-K - Disc Medicine, Inc. (0001816736) (Filer)
8-K - Disc Medicine, Inc. (0001816736) (Filer)
144 - Disc Medicine, Inc. (0001816736) (Subject)
8-K - Disc Medicine, Inc. (0001816736) (Filer)
144 - Disc Medicine, Inc. (0001816736) (Subject)
8-K - Disc Medicine, Inc. (0001816736) (Filer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
HC Wainwright & Co. analyst Douglas Tsao reiterates Disc Medicine (NASDAQ:IRON) with a Buy and maintains $70 price target.
BMO Capital analyst Evan Seigerman reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $50 to $70.
U.S. stocks traded mixed toward the trading, with the Dow Jones index falling around 0.2% on Friday. The Dow traded down 0.24% to 38,554.69 while the NASDAQ rose 0.07% to 17,680.01. The S&P 500 also fell, dropping, 0.10% to 5,428.33. . Check This Out: Top 2 Materials Stocks That May Collapse This Quarter Leading and Lagging SectorsCommunication services shares jumped by 0.5% on Friday. In trading on Friday, industrials shares fell by 1.2%. Top Headline The total number of active U.S. oil rigs declined by four to 488 rigs this week, Baker Hughes Inc reported. Equities Trading UP
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results. AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for a loss of 1 cent per share. The company reported quarterly sales of $40.42 million topping estimates of $37.90 million, according to data from Benzinga Pro. AMMO shares dipped 19.1% to $2.0306 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) shares jumped 345% to $6.06. SRIVARU Holding Limited (NASDAQ:SVMH) gained 150% to $0.3852 after the company announced it will begin accepting paid reserva
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) shares moved upwards by 37.4% to $2.9 during Friday's regular session. The market value of their outstanding shares is at $7.2 million. CNS Pharma (NASDAQ:CNSP) stock rose 35.86% to $4.92. The market value of their outstanding shares is at $1.9 million. Longeveron (NASDAQ:LGVN) shares moved upwards by 23.23% to $3.31. The market value of their outstanding shares is at $21.0 million. iSpecimen (NASDAQ:ISPC) stock moved upwards by 19.44% to $0.49. The market value of their outstanding shares is at $4.8 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock rose 17.8% to $3.32. The market value of their outstanding shares is at $1.9 million. Di
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Friday. The Dow traded down 0.63% to 38,403.11 while the NASDAQ fell 0.07% to 17,655.10. The S&P 500 also fell, dropping, 0.37% to 5,413.41 . Check This Out: Top 2 Materials Stocks That May Collapse This Quarter Leading and Lagging SectorsCommunication services shares jumped by 0.4% on Friday. In trading on Friday, industrials shares fell by 2.1%. Top Headline The University of Michigan consumer sentiment declined for a third consecutive month to a reading of 65.6 in June, notching the lowest level since November, compared to 69.1 in May and down from market estimates
HC Wainwright & Co. analyst Douglas Tsao reiterates Disc Medicine (NASDAQ:IRON) with a Buy and maintains $70 price target.
U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Friday. Shares of Hasbro, Inc. (NASDAQ:HAS) rose sharply during Friday's session after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $70 to $80. Hasbro shares gained 5.5% to $61.22 on Friday. Here are some other big stocks recording gains in today’s session. Disc Medicine, Inc. (NASDAQ:IRON) shares gained 15.6% to $45.29. Disc Medicine announced a $178 million underwritten offering of 4.944 million shares at $36 per share. UroGen Pharma Ltd. (NASDAQ:URGN) rose 15.4% to $20.19. UroGen Pharma recently announced an 82.3% 12-month duration of response i